Searched for: subject%3A%22subtypes%22
(1 - 6 of 6)
document
Coutinho de Almeida, Rodrigo (author), Mahfouz, A.M.E.T.A. (author), Mei, Hailiang (author), Houtman, Evelyn (author), den Hollander, Wouter (author), Soul, Jamie (author), Suchiman, Eka (author), Nelissen, R.G.H.H. (author), Reinders, M.J.T. (author)
OBJECTIVE: To identify OA subtypes based on cartilage transcriptomic data in cartilage tissue and characterize their underlying pathophysiological processes and/or clinically relevant characteristics. METHODS: This study includes n = 66 primary OA patients (41 knees and 25 hips), who underwent a joint replacement surgery, from which...
journal article 2021
document
Sontrop, HMJ (author), Reinders, M.J.T. (author), Moerland, Perry D. (author)
Background: At the molecular level breast cancer comprises a heterogeneous set of subtypes associated with clear differences in gene expression and clinical outcomes. Single sample predictors (SSPs) are built via a two-stage approach consisting of clustering and subtype predictor construction based on the cluster labels of individual cases. SSPs...
journal article 2016
document
Taskesen, E. (author), Babaei, S. (author), Reinders, M.J.M. (author), De Ridder, J. (author)
Background Acute Myeloid Leukemia (AML) is characterized by various cytogenetic and molecular abnormalities. Detection of these abnormalities is important in the risk-classification of patients but requires laborious experimentation. Various studies showed that gene expression profiles (GEP), and the gene signatures derived from GEP, can be used...
journal article 2015
document
Sontrop, H.M.J. (author)
Microarrays offer biologists an exciting tool that allows the simultaneous assessment of gene expression levels for thousands of genes at once. At the time of their inception, microarrays were hailed as the new dawn in cancer biology and oncology practice with the hope that within a decade diseases like breast cancer would be solved. Various...
doctoral thesis 2015
document
Roepman, P. (author), Schlicker, A. (author), Tabernero, J. (author), Majewski, I. (author), Tian, S. (author), Moreno, V. (author), Snel, M.H. (author), Chresta, C.M. (author), Rosenberg, R. (author), Nitsche, U. (author), Macarulla, T. (author), Capella, G. (author), Salazar, R. (author), Orphanides, G. (author), Wessels, L.F.A. (author), Bernards, R. (author), Simon, I.M. (author)
In most colorectal cancer (CRC) patients, outcome cannot be predicted because tumors with similar clinicopathological features can have differences in disease progression and treatment response. Therefore, a better understanding of the CRC biology is required to identify those patients who will benefit from chemotherapy and to find a more...
journal article 2013
document
Schlicker, A. (author), Beran, G. (author), Chresta, C.M. (author), McWalter, G. (author), Pritchard, A. (author), Weston, S. (author), Runswick, S. (author), Davenport, S. (author), Heathcote, K. (author), Alferez Castro, D. (author), Orphanides, G. (author), French, T. (author), Wessels, L.F.A. (author)
Background Colorectal cancer (CRC) is a heterogeneous and biologically poorly understood disease. To tailor CRC treatment, it is essential to first model this heterogeneity by defining subtypes of patients with homogeneous biological and clinical characteristics and second match these subtypes to cell lines for which extensive pharmacological...
journal article 2012
Searched for: subject%3A%22subtypes%22
(1 - 6 of 6)